ArticleOxford medical case reports2025
Paraneoplastic minimal change disease in malignant thymoma: a rare association progressing to end-stage renal disease.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A case of anti-nephrin antibody-positive, steroid-dependent nephrotic syndrome with successful discontinuation of immunosuppressants following rituximab.Oxford medical case reports · 2026Article
- Immune dysregulation in thymoma: a potential mechanistic link to secondary lung cancer-a case report.Mediastinum (Hong Kong, China) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thymoma, commonly seen in middle-aged and elderly individuals, is associated with autoimmune disorders. While renal involvement is rare, its occurrence remains poorly characterized. Case Presentation: We report a 24-year-old female with a ten-year history of malignant thymoma who developed nephrotic syndrome. Renal biopsy revealed minimal change disease (MCD), a rare paraneoplastic manifestation of thymoma. Despite treatment with steroids and rituximab, her renal function deteriorated, leading to end-stage renal disease (ESRD). This case underscores the challenges of managing paraneoplastic glomerular disease and highlights the need for better understanding of such rare associations. Conclusion: Thymoma-related glomerular diseases, often linked to immune dysregulation, pose significant treatment challenges. Recognizing these associations may guide more effective management strategies, particularly for patients unresponsive to steroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.